The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Oscar Braun

Physician

Default user image.

Benefits of Neurohormonal Therapy in Patients With Continuous-Flow Left Ventricular Assist Devices

Author

  • Rayan Yousefzai
  • Michela Brambatti
  • Hao A Tran
  • Rachel Pedersen
  • Oscar Ö Braun
  • Tina Baykaner
  • Roxana Ghashghaei
  • Nasir Z Sulemanjee
  • Omar M Cheema
  • Matthew Rappelt
  • Carmela Baeza
  • Abdulaziz Alkhayyat
  • Yang Shi
  • Victor Pretorius
  • Barry Greenberg
  • Eric Adler
  • Vinay Thohan

Summary, in English

Left ventricular assist devices (LVADs) have dramatically improved short-term outcomes among patients with advanced heart failure. While neurohormonal blockade (NHB) is the cornerstone of treatment for patients with heart failure with reduced ejection fraction, its effect after LVAD placement has not been established. We reviewed medical records of 307 patients who underwent primary LVAD implantation from January 2006 to September 2015 at two institutions in the United States. Patients were followed for at least 2 years post-LVAD implantation or until explantation, heart transplantation, or death. Cox regression analysis stratifying on center was used to assess associations with mortality. Neurohormonal blockade use was treated as a time-dependent predictor. Stepwise selection indicated treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEIs/ARBs) (hazard ratio [HR] = 0.53 [0.30-0.95], p = 0.03), age at the time of implantation (HR = 1.28 [1.05-1.56] per decade, p = 0.02), length of stay postimplantation (HR = 1.16 [1.11-1.21] per week, p < 0.01) and INTERMACS profile of 1 or 2 (HR = 1.86 [1.17-2.97], p < 0.01) were independent predictors of mortality. In this large, retrospective study, treatment with ACEIs or ARBs was an independent factor associated with decreased mortality post-LVAD placement.

Publishing year

2020

Language

English

Pages

409-414

Publication/Series

ASAIO Journal

Volume

66

Issue

4

Document type

Journal article

Publisher

Amercian Society of Artificial Internal Organs

Topic

  • Clinical Medicine

Status

Published

ISBN/ISSN/Other

  • ISSN: 1538-943X